BRIEF-Curevac Q1 Revenue Eur 900 Thousand

Reuters

2025/05/20

May 20 (Reuters) - CUREVAC NV 5CV.DE:

Q1 REVENUE EUR 900 THOUSAND
Q1 PRETAX PROFIT EUR -51.7 MILLION
Q1 EBIT EUR -54.7 MILLION
STRONG CASH AND CASH EQUIVALENTS POSITION OF EUR 438.3 MILLION AS OF MARCH 31, 2025
REAFFIRMING EXPECTED CASH RUNWAY INTO 2028
YEAR-ON-YEAR DECREASE IN REVENUES WAS PRIMARILY DRIVEN BY LOWER REVENUES FROM GSK FOLLOWING RESTRUCTURING OF PARTNERSHIP IN JULY 2024 FROM A COLLABORATION INTO A LICENCE AGREEMENT AS WELL AS LOWER SALES TO CRISPR THERAPEUTICS
NET FINANCIAL RESULT FOR Q1 OF 2025 AMOUNTED TO EUR 3.0 MILLION

Source text: ID:nEQ75HTCZa

Further company coverage: 5CV.DE

(Gdansk Newsroom)

((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2536619043"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536619043\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2536619043?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-20 19:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536619043","market":"nz","top_or_hot":-1,"title":"BRIEF-Curevac Q1 Revenue Eur 900 Thousand","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Curevac Q1 Revenue Eur 900 Thousand</title></head><body><p><span>May 20 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/0A9E.UK\">CUREVAC NV</a> <span>5CV.DE</span>:</p><ul><li><p>Q1 REVENUE EUR 900 THOUSAND</p></li><li><p>Q1 PRETAX PROFIT EUR -51.7 MILLION</p></li><li><p>Q1 EBIT EUR -54.7 MILLION</p></li><li><p>STRONG CASH AND CASH EQUIVALENTS POSITION OF EUR 438.3 MILLION AS OF MARCH 31, 2025</p></li><li><p>REAFFIRMING EXPECTED CASH RUNWAY INTO 2028</p></li><li><p>YEAR-ON-YEAR DECREASE IN REVENUES WAS PRIMARILY DRIVEN BY LOWER REVENUES FROM GSK FOLLOWING RESTRUCTURING OF PARTNERSHIP IN JULY 2024 FROM A COLLABORATION INTO A LICENCE AGREEMENT AS WELL AS LOWER SALES TO CRISPR THERAPEUTICS</p></li><li><p>NET FINANCIAL RESULT FOR Q1 OF 2025 AMOUNTED TO EUR 3.0 MILLION</p></li></ul><p>Source text: <span>ID:nEQ75HTCZa</span></p><p>Further company coverage: <span>5CV.DE</span></p><p> (Gdansk Newsroom)</p><p> ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Curevac Q1 Revenue Eur 900 Thousand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Curevac Q1 Revenue Eur 900 Thousand\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-20 19:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Curevac Q1 Revenue Eur 900 Thousand</title></head><body><p><span>May 20 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/0A9E.UK\">CUREVAC NV</a> <span>5CV.DE</span>:</p><ul><li><p>Q1 REVENUE EUR 900 THOUSAND</p></li><li><p>Q1 PRETAX PROFIT EUR -51.7 MILLION</p></li><li><p>Q1 EBIT EUR -54.7 MILLION</p></li><li><p>STRONG CASH AND CASH EQUIVALENTS POSITION OF EUR 438.3 MILLION AS OF MARCH 31, 2025</p></li><li><p>REAFFIRMING EXPECTED CASH RUNWAY INTO 2028</p></li><li><p>YEAR-ON-YEAR DECREASE IN REVENUES WAS PRIMARILY DRIVEN BY LOWER REVENUES FROM GSK FOLLOWING RESTRUCTURING OF PARTNERSHIP IN JULY 2024 FROM A COLLABORATION INTO A LICENCE AGREEMENT AS WELL AS LOWER SALES TO CRISPR THERAPEUTICS</p></li><li><p>NET FINANCIAL RESULT FOR Q1 OF 2025 AMOUNTED TO EUR 3.0 MILLION</p></li></ul><p>Source text: <span>ID:nEQ75HTCZa</span></p><p>Further company coverage: <span>5CV.DE</span></p><p> (Gdansk Newsroom)</p><p> ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CVAC","symbol_name":"CureVac B.V.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nPLX7815BD:1","article_id":"2536619043","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536619043","pubTimestamp":1747739095,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Curevac Q1 Revenue Eur 900 ThousandMay 20 (Reuters) - CUREVAC NV 5CV.DE:Q1 REVENUE EUR 900 THOUSANDQ1 PRETAX PROFIT EUR -51.7 MILLIONQ1 EBIT EUR -54.7 MILLIONSTRONG CASH AND CASH EQUIVALENTS POS","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CVAC":"CureVac B.V."},"translate_title":"简介-Curevac第一季度收入90万欧元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVAC":0.9},"content_text":"BRIEF-Curevac Q1 Revenue Eur 900 ThousandMay 20 (Reuters) - CUREVAC NV 5CV.DE:Q1 REVENUE EUR 900 THOUSANDQ1 PRETAX PROFIT EUR -51.7 MILLIONQ1 EBIT EUR -54.7 MILLIONSTRONG CASH AND CASH EQUIVALENTS POSITION OF EUR 438.3 MILLION AS OF MARCH 31, 2025REAFFIRMING EXPECTED CASH RUNWAY INTO 2028YEAR-ON-YEAR DECREASE IN REVENUES WAS PRIMARILY DRIVEN BY LOWER REVENUES FROM GSK FOLLOWING RESTRUCTURING OF PARTNERSHIP IN JULY 2024 FROM A COLLABORATION INTO A LICENCE AGREEMENT AS WELL AS LOWER SALES TO CRISPR THERAPEUTICSNET FINANCIAL RESULT FOR Q1 OF 2025 AMOUNTED TO EUR 3.0 MILLIONSource text: ID:nEQ75HTCZaFurther company coverage: 5CV.DE (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}